The award-winning mass spectrometer, introduced in June 2019, incorporates intelligent ‘designed-in’ innovations such as embedded sensors that monitor instrument health and provide early maintenance feedback.
Described by The Analytical Scientist as ‘a small, high-performance system that enables MS analysis without the requirement for extensive training,’ the Agilent InfinityLab LC/MSD iQ system is specifically designed for chemists and chromatographers, to be an easy-to-use mass selective detector that provides added specificity and selectivity.
“The pharma industry seems to be on the cusp of significant change,” said Stephanie Sutton, editor of The Medicine Maker. “Especially with the emergence of advanced medicines, such as cell and gene therapies, and new digital technologies with the potential to transform how the industry manufactures medicines – large and small. We’re proud to shine a light on the important contribution made by vendors to the manufacture of medicines and, ultimately, the treatment of patients.”
“Winning these two awards is especially gratifying, as it confirms the value of our continued emphasis on innovation,” said Monty Benefiel, Agilent vice president, and general manager of the company’s Mass Spectrometry Division. “It is our hope that the InfinityLab LC/MSD iQ system will help our customers do what they do best: improve the world around us.”